Unlocking Insights into Discoid Lupus Erythematosus: A Call for Collaboration

Discoid lupus erythematosus (DLE) is an autoimmune condition that primarily affects the skin, and it's considered a subtype of chronic cutaneous lupus erythematosus (CLE). The most prevalent form of CLE, DLE can cause scaly, inflamed patches on the scalp, face, and ears, leading to permanent scarring, changes in skin color, and hair loss. According to Linda Zhu, MD, PhD, senior medical director at Amgen, 'The effects of DLE aren't limited to what can be seen on the skin.'

Zhu emphasizes that understanding the full patient experience is crucial for advancing research efforts. The lack of treatment options and approved targeted therapies puts people living with DLE in a difficult position.

Researchers are studying the proteins and immune pathways involved in DLE to develop treatments that can address the underlying processes driving inflammation. Collaboration between patients, care partners, advocates, researchers, and the broader community is essential for advancing understanding and improving lives. Louise Vetter, president and CEO of the Lupus Foundation of America, highlights the importance of patient voices informing progress and remaining at the center of efforts to advance care.